Trevena Reports Second Quarter 2019 Results

8/7/19

CHESTERBROOK, Pa., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today reported its financial results for the second quarter ended June 30, 2019, and provided an overview of its recent operational highlights.

“We made substantive progress in the second quarter on the key activities to support resubmission of the NDA for oliceridine and advancement of our pipeline,” said Carrie Bourdow, President and Chief Executive Officer. “Subject enrollment in our healthy volunteer study for oliceridine is progressing well, and we remain focused on delivering topline data next quarter. We’re also excited to continue development efforts for our other pipeline assets, including the acute migraine study for TRV250, which is slated to start next quarter.”

Second Quarter and Recent Corporate Highlights:

  • Strengthened leadership team. The Company recently announced the appointment of Barry Shin as Senior Vice President and Chief Financial Officer. Mr. Shin brings over 17 years of investment banking and corporate advisory experience focused in the biopharmaceuticals sector, including in the Healthcare Investment Banking groups of Mizuho Securities, Guggenheim Securities, and Piper Jaffray.
  • Initiated healthy volunteer QT interval study for oliceridine. In June, the Company announced initiation of its single-site, three-period crossover, healthy volunteer study for oliceridine. The primary objective of the study is to collect the additional QT interval data requested by the U.S. Food and Drug Administration (FDA) for the resubmission of the NDA for oliceridine.

    Study enrollment is on track to support topline data readout in the fourth quarter of 2019. As of today, over half of study subjects have begun dosing, with more than 20 subjects receiving the maximum daily dose of 27 mg of oliceridine, a key FDA requirement of the study design. The Company continues to expect to resubmit the NDA for oliceridine as early as possible in the first quarter of 2020.

  • Advanced acute migraine proof-of-concept study protocol for TRV250. This double-blind, placebo-controlled clinical study will enroll approximately 120 migraineurs in a validated nitroglycerin (NTG) provocation migraine model. Migraineurs will receive a 20 mg subcutaneous dose of TRV250 or placebo. Target engagement will be determined by the reduction in the number of subjects who experience a sustained NTG-induced headache. The Company continues to expect to initiate this study in the fourth quarter of 2019.
  • Submitted four oliceridine abstracts, all of which were accepted for presentation at the 2019 Annual Meeting of the American Society of Anesthesiologists (ASA). The Company today announced that all abstracts submitted to the 2019 ASA meeting have been accepted for presentation, including one that will be featured in the Best of Clinical Science session. The meeting will take place October 19-23, 2019, at the Orange County Convention Center in Orlando, Florida. The presentations will feature data highlighting the safety profile of oliceridine compared to IV morphine.

Presentation details:

  1. Improved safety of opioid analgesic Oliceridine compared to Morphine assessed by utility function analysis (oral presentation, Best of Abstracts: Clinical Science featured session)
    • Saturday, October 19, 2019 from 1:00 p.m. – 3:00 p.m. EST
    • Sunday, October 20, 2019 from 8:00 a.m. – 9:30 a.m. EST
  2. Low Incidence Of Opioid-induced Respiratory Depression Observed With Oliceridine Regardless Of Age Or Body Mass Index (e-poster, abstract #2228)
    • Sunday, October 20, 2019 from 1:30 p.m. – 2:00 p.m. EST
  3. Lower Incidence Of Postoperative Opioid-induced Respiratory Depression With Oliceridine Compared To Morphine: A Retrospective Analysis (e-poster, abstract #2232)
    • Sunday, October 20, 2019 from 2:00 p.m. – 2.30 p.m. EST
  4. Oliceridine (TRV130) Demonstrates Less Opioid-induced Respiratory Depression Than Morphine (M) As Measured By The Average Cumulative Duration Of Dosing Interruption In Patients Being Treated For Acute Post-surgical Pain (e-poster, abstract #3069)
    • Monday, October 21, 2019 from 10:00 a.m. – 10:30 a.m. EST

All abstracts will be made available on https://www.asahq.org/annualmeeting/education/sessions.

  • Published clinical data for oliceridine. In June, the Company announced the publication of pivotal Phase 3 results in the journal Pain Practice on the effects of oliceridine for the management of moderate to severe acute pain following soft tissue surgery.

Financial Results for Second Quarter 2019

For the second quarter of 2019, the Company reported a net loss attributable to common stockholders of $4.7 million, or $0.05 per share, compared to $9.3 million, or $0.13 per share, for the second quarter of 2018. This decrease is primarily due to a decrease in expenditures resulting from the 2018 restructuring and reduction in force and associated cost-saving initiatives.

Cash, cash equivalents, and marketable securities were $54.0 million as of June 30, 2019. The Company believes its cash, cash equivalents, and marketable securities as of June 30, 2019, together with interest thereon, to be sufficient to fund the Company’s operating expenses, debt service, and capital expenditure requirements for at least twelve months following the date of this filing, into the third quarter of 2020.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System conditions. The Company has four novel and differentiated investigational drug candidates, including IV oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the acute treatment of migraine, and TRV734 for maintenance treatment of opioid use disorder. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain.